Ralph Naumann
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ralph Naumann has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Gerhard Ehninger
2 shared publicationsJan Bredow
2 shared publicationsJoachim Kropp
2 shared publicationsThomas Kittner
2 shared publicationsAstrid Vaic
Department of Internal Medicine I
1 shared publicationBettina Beuthien-Baumann
1 shared publication
Latest Publications
- 1 September 2002
- Published by Elsevier in Clinical Lymphoma
- Vol. 3 (2) , 121-124
Simultaneous Occurrence of Hodgkin's Lymphoma and Eosinophilic Granuloma: A Potential Pitfall in Positron Emission Tomography Imaging
- 1 September 2002
- Published by Elsevier in Clinical Lymphoma
- Vol. 3 (2) , 121-124
Simultaneous Occurrence of Hodgkin's Lymphoma and Eosinophilic Granuloma: A Potential Pitfall in Positron Emission Tomography Imaging
- Open Access
- 20 December 2001
- Published by Wiley in British Journal of Haematology
- Vol. 115 (4) , 793-800
Prognostic value of positron emission tomography in the evaluation of post‐treatment residual mass in patients with Hodgkin's disease and non‐Hodgkin's lymphoma
The prognostic value of 18F‐fluorodeoxyglucose (FDG) positron emission tomography (PET) in the assessment of post‐treatment residual masses in patients with Hodgkin's disease (HD) or non‐Hodgkin's lymphomas (NHL) was evaluated. We prospectively studied 58 patients with HD (n = 43) or NHL (n = 15) who had post‐therapeutic complete remission with residual masses (CRu) indicated by computerized tomography. Analysis of 62 residual locations by FDG‐PET was performed separately for HD and NHL. Patients with a PET‐positive residual mass [standardized uptake value (SUV) > 3] had a recurrence rate of 62·5% (5/8 patients), whereas patients with PET‐negative residual mass (SUV ≤ 3·0) showed a recurrence rate of 4% (2/50 patients, P = 0·004). A positive FDG‐PET study correlated with a significantly poorer progression‐free survival (P < 0·00001). No recurrence occurred in any of the 39 HD patients with a negative PET scan (negative predictive value, 100%). Four out of four NHL patients with a positive PET study relapsed (positive predictive value, 100%). In conclusion, FDG‐PET is a suitable non‐invasive method with a high degree of accuracy in the prediction of early recurrence in lymphoma patients with CRu.
- 20 December 2001
- Published by Wiley in British Journal of Haematology
- Vol. 115 (4) , 793-800
Open AccessPrognostic value of positron emission tomography in the evaluation of post‐treatment residual mass in patients with Hodgkin's disease and non‐Hodgkin's lymphoma
The prognostic value of 18F‐fluorodeoxyglucose (FDG) positron emission tomography (PET) in the assessment of post‐treatment residual masses in patients with Hodgkin's disease (HD) or non‐Hodgkin's lymphomas (NHL) was evaluated. We prospectively studied 58 patients with HD (n = 43) or NHL (n = 15) who had post‐therapeutic complete remission with residual masses (CRu) indicated by computerized tomography. Analysis of 62 residual locations by FDG‐PET was performed separately for HD and NHL. Patients with a PET‐positive residual mass [standardized uptake value (SUV) > 3] had a recurrence rate of 62·5% (5/8 patients), whereas patients with PET‐negative residual mass (SUV ≤ 3·0) showed a recurrence rate of 4% (2/50 patients, P = 0·004). A positive FDG‐PET study correlated with a significantly poorer progression‐free survival (P < 0·00001). No recurrence occurred in any of the 39 HD patients with a negative PET scan (negative predictive value, 100%). Four out of four NHL patients with a positive PET study relapsed (positive predictive value, 100%). In conclusion, FDG‐PET is a suitable non‐invasive method with a high degree of accuracy in the prediction of early recurrence in lymphoma patients with CRu.